Virax Non Current Liabilities Total from 2010 to 2025
| VRAX Stock | USD 1.16 0.08 6.45% |
Non Current Liabilities Total | First Reported 2010-12-31 | Previous Quarter 158.7 K | Current Value 232.4 K | Quarterly Volatility 172 K |
Check Virax Biolabs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virax Biolabs' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 88.1 K or Interest Expense of 28.3 K, as well as many indicators such as Price To Sales Ratio of 10.3, Dividend Yield of 0.0 or PTB Ratio of 0.26. Virax financial statements analysis is a perfect complement when working with Virax Biolabs Valuation or Volatility modules.
Virax | Non Current Liabilities Total |
Latest Virax Biolabs' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Virax Biolabs Group over the last few years. It is Virax Biolabs' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virax Biolabs' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Virax Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 234,967 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 73.19 | |
| Mean Deviation | 76,438 | |
| Median | 212,835 | |
| Standard Deviation | 171,974 | |
| Sample Variance | 29.6B | |
| Range | 846.5K | |
| R-Value | 0.07 | |
| Mean Square Error | 31.5B | |
| R-Squared | 0 | |
| Significance | 0.80 | |
| Slope | 2,545 | |
| Total Sum of Squares | 443.6B |
Virax Non Current Liabilities Total History
About Virax Biolabs Financial Statements
Virax Biolabs investors use historical fundamental indicators, such as Virax Biolabs' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virax Biolabs. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 158.7 K | 232.4 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.